3-(4-furan-3-yl-phenylamino)-1-methyl-1H-quinoxalin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-(4-furan-3-yl-phenylamino)-1-methyl-1H-quinoxalin-2-one
• 英文别名: 3-[4-(furan-3-yl)anilino]-1-methylquinoxalin-2-one
• 化学式: C₁₉H₁₅N₃O₂
• 分子量: 317.347
• InChiKey: CVBCPYIWRQSVOE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-甲基-1,2-苯二胺 在 四(三苯基膦)钯 、 sodium carbonate 、 三乙胺 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 乙二醇二甲醚 、 二氯甲烷 、 甲苯 、 乙腈 为溶剂， 生成 3-(4-furan-3-yl-phenylamino)-1-methyl-1H-quinoxalin-2-one
  参考文献：
  名称：

  Synthesis and evaluation of 3-anilino-quinoxalinones as glycogen phosphorylase inhibitors

  摘要：

  A series of 3-anilino-quinoxalinones has been identified as a new class of glycogen phosphorylase inhibitors. The lead compound I was identified through high throughput screening as well as through pharmacophore-based electronic screening. Modifications were made to the scaffold of 1 to produce novel analogues, some of which are 25 times more potent than the lead compound. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.07.021

文献信息

• Quinoxalinones
  申请人：Beavers Pat Mary

  公开号：US20050148586A1

  公开（公告）日：2005-07-07

  The invention features quinoxalinones, pharmaceutical compositions containing them and methods of using them to treat, for example, diabetes.

  这项发明涉及喹喔啉酮，包含它们的药物组合物以及使用它们治疗糖尿病等疾病的方法。
• (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1711184A1

  公开（公告）日：2006-10-18
• [EN] (3-OXO-3, 4-DIHYDRO-QUINOXALIN-2-YL-AMINO) -BENZAMIDE DERIVATIVES AND RELATED COMPOUND AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY<br/>[FR] DERIVES DE (3-OXO-3, 4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE ET COMPOSES AFFERENTS COMME INHIBITEURS DE LA GLYCOGENE PHOSPHORYLASE DANS LE TRAITEMENT DU DIABETE ET DE L'OBESITE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005067932A1

  公开（公告）日：2005-07-28

  The invention features pharmaceutically active quinoxalinones of formula (1), compositions containing them, and methods of making and using theme: Formula (I) wherein R1 is H, C 1-6 alkyl, or halo; R2 is H or halo; R3 is H, C 1-6 alkyl, X is N or CH; Y is a covalent bond, -NHCO- or -CONH-; Z is phenyl or a 5 or 6-membered heterocyclyl with between l and 2 heteroatoms independently selected from N, O, and S; and n is 0, 1 or 2; or a pharmaceutically acceptable salt, ester, amide, hydrate, or solvate thereof; as well as their use as glycogen phosphorylase inhibitors for the treatment of i diabetes and obesity.